DePuy Synthes Secures Exclusive Commercialization Rights for North America and Australia

CG Bio, a specialist in bio-regenerative medicine, announced on May 27 that it has entered into a global clinical development and exclusive commercialization agreement for its bone substitute product line, 'Novosis', with DePuy Synthes, a global orthopedic solutions company, targeting the United States, Canada, and Australia markets.


'Novosis Putty' product image. CGBio

'Novosis Putty' product image. CGBio

View original image

Under this agreement, DePuy Synthes has secured exclusive commercialization rights for the Novosis product line in the United States, Canada, and Australia. Both companies plan to jointly pursue global clinical trials and regulatory approvals, including Investigational Device Exemption (IDE) and Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA).


Previously, CG Bio signed an exclusive distribution and promotion agreement with Johnson & Johnson last year for the Novosis product in Korea, Taiwan, Thailand, India, Hong Kong, and Macau, and later expanded the collaboration to include Malaysia and Singapore. With this new agreement, the partnership now covers North America and Australia, further strengthening CG Bio’s foundation for global market expansion beyond the Asia-Pacific region.


The two companies will establish a joint steering committee to select individual projects and collaborate on development strategies. The IDE clinical trial in the United States is being prepared with the goal of commencing in the second half of this year.


North America is considered a key region in the global bone substitute market. According to market research firm Fortune Business Insights, the global bone substitute market is expected to grow from approximately $3.78 billion in 2022 to about $5.71 billion by 2029, with the North American market forming the largest single regional market at approximately $1.53 billion.


Novosis is a bone substitute product line that combines rhBMP-2 (recombinant human bone morphogenetic protein-2) based bone regeneration technology with CG Bio's sustained-release carrier platform technology. CG Bio's proprietary SLOREL™ sustained-release carrier technology is designed to control the release of rhBMP-2 and create a stable environment for bone regeneration. In addition, the application of a calcium hydroxyapatite (CaHA)-based ceramic scaffold allows for the realization of a structural environment similar to real bone.


The company highlighted that the global expansion potential of Novosis is drawing attention, especially as demand increases in spinal fusion and bone regeneration procedures where both bone union performance and ease of handling are required.



Hyunseung Yoo, CEO of CG Bio, stated, "This agreement is significant as it expands our partnership from the existing Asia-Pacific collaboration to now include the North American and Oceania markets. Through global regulatory approvals and commercialization—including FDA IDE and PMA—we aim to establish Novosis as a new standard in the global bone regeneration market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing